Lundbeck to restructure R&D, shedding up to 160 jobs

pharmafile | June 10, 2020 | News story | Manufacturing and Production, Research and Development Lundbeck, pharma, staff cuts 

Danish neuroscience specialist Lundbeck has announced it will be implementing a restructure of its Research & Development operations – a move which may result in the culling of up to 160 staff.

The company says that this reorganisation will enable it to better “strengthen and advance” its neuroscience product pipeline across all phases of development.

Should the plan go ahead, it is expected that the move could result in the termination of between 130 and 160 members of staff, with around 100 of those cuts being made in Denmark. The company currently employs around 5,800 employees, and around 1,780 of these work in Denmark.

Johan Luthman, Executive Vice President of R&D at Lundbeck, commented on the plans: “The proposed changes will allow us to fully execute on our strategy in the years to come and rebuild our pipeline with innovative programs with strong potential to deliver highly impactful treatments for patients with brain disorders. Through this we will support Lundbeck in becoming the premier neuroscience company, globally.” 

Advertisement

While many companies have been forced to reorganise or downsize as a result of the ongoing COVID-19 pandemic, there was no indication that this move is an example of that. The plan forms part of Lundbeck’s Expand and Invest to Grow-strategy which aims to focus the company’s R&D operations on its most promising products, with particular emphasis placed on the efficacy of emerging technologies and flexibility of approach in making this a reality.

Matt Fellows

Related Content

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

blood_test

Johnson & Johnson announces successful results from trial for myeloma treatment

Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed …

Bend Bioscience adds commercial spray drying facility to Georgia site

Bend Bioscience has announced the addition of a commercial-scale spray dryer and a Gerteis dry …

The Gateway to Local Adoption Series

Latest content